| Subject: | FDA Informs Healthcare Professionals of Reports of Risk of PML in Patients Receiving Tysabri |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 22 Sep 2009 - 11:00 am |
| Audience: Neurological healthcare professionals, patients The Food and Drug Administration (FDA) continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri. Tysabri was approved by the FDA for the treatment of relapsing forms of multiple sclerosis (MS) in November 2004 and for moderately to severely active Crohn's disease in January 2008. From July 2006, (when Tysabri marketing resumed) to September 8, 2009, 13 reported cases... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
